ArticleBMC pulmonary medicine2016
Clinical and economic burden of idiopathic pulmonary fibrosis: a retrospective cohort study.
Article in BMC pulmonary medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
50 citing papers in PubMed, 5 syntheses or guidelines pooled it.
- Economic burden and cost drivers of interstitial lung disease: a systematic review.The European journal of health economics : HEPAC : health economics in prevention and care · 2026Pooled it
- Economic Burden of Idiopathic Pulmonary Fibrosis: Updated Evidence on Costs and Resource Use.PharmacoEconomics · 2026Pooled it
- Incidence and prevalence of interstitial lung diseases worldwide: a systematic literature review.BMJ open respiratory research · 2023Pooled it
- A systematic review on the economic burden of interstitial lung disease and the cost-effectiveness of current therapies.BMC pulmonary medicine · 2022Pooled it
- The Burden of Illness of Idiopathic Pulmonary Fibrosis: A Comprehensive Evidence Review.PharmacoEconomics · 2018Pooled it
- Exosomes as Disease-Informed Nanoplatforms for Pulmonary Fibrosis: From Pathogenic Signaling to Precision Diagnosis and Therapy.Pharmaceutics · 2026Review
- Hospitalisations in patients with idiopathic pulmonary fibrosis: insights from the IPF-PRO Registry and EMPIRE Registry.ERJ open research · 2026Article
- Real-World Health Care Resource Utilization and Economic Burden Among Patients with Idiopathic Pulmonary Fibrosis in Commercially Insured and Medicare Advantage Populations in the United States.Journal of health economics and outcomes research · 2026Article
- Rewiring the scar: translational advances in cardiac fibrosis.The Korean journal of physiology & pharmacology : official journal of the Korean Physiological Society and the Korean Society of Pharmacology · 2025Review
- Global epidemiology and burden of interstitial lung disease.The Lancet. Respiratory medicine · 2025Review
- Pulmonary fibrosis: from mechanisms to therapies.Journal of translational medicine · 2025Review
- Unravelling the transcriptomic characteristics of bronchoalveolar lavage in post-covid pulmonary fibrosis.BMC medical genomics · 2025Article
- Identifying central symptom clusters and correlates among post-COVID-19 pulmonary fibrosis patients: a network analysis.Frontiers in medicine · 2025Article
- Cannabinoid receptor ligands modulate fibrosis and inflammation in idiopathic pulmonary fibrosis: a preliminary study.Turkish journal of biology = Turk biyoloji dergisi · 2024Article
- Plumbagin attenuates Bleomycin-induced lung fibrosis in mice.Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology · 2022Article
- Article
- The sialidase NEU3 promotes pulmonary fibrosis in mice.Respiratory research · 2022Article
- Burden of illness in progressive fibrosing interstitial lung disease.Journal of managed care & specialty pharmacy · 2022Article
- Exploring the comorbidity mechanisms between asthma and idiopathic pulmonary fibrosis and the pharmacological mechanisms of Bu-Shen-Yi-Qi decoction therapy via network pharmacology.BMC complementary medicine and therapies · 2022Article
- Cost-effectiveness of the anti-fibrotics for the treatment of idiopathic pulmonary fibrosis in the United States.BMC pulmonary medicine · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIdiopathic pulmonary fibrosis (IPF) is a devastating condition with a variable course. Not uncommonly, IPF patients are hospitalized for respiratory-related causes, including disease worsening. This study aimed to characterize the prevalence, and economic and health care burden of IPF.
methodsRetrospective insurance claims data collected yearly between January 1, 2009 and December 31, 2011, were used to determine prevalence and calculate all-cause and respiratory-related resource utilization and costs. Patients had at least one inpatient claim or two outpatient claims for IPF (ICD-9-CM code 516.3). Results for health care burden are reported for the 2011 cohort (similar findings in 2009-2010). Costs are reported in 2011 US dollars ($).
resultsPatients with IPF had a mean age of 69.8-71.3 years. Overall prevalence for IPF was 28.8, 28.1 and 19.8 per 100,000 insured persons in 2009, 2010 and 2011. In each year, prevalence increased with age. In 2011, 37.7% of patients were hospitalized at least once for any cause; 19.5% for respiratory-related reasons. Also in 2011, the mean number of all-cause outpatient visits and respiratory-related office visits was 18.5 and 5.7 per patient, respectively. All-cause health care costs in 2011 were $59,379 per patient; 36.6% of costs ($21,732) were respiratory related.
conclusionsThe prevalence of IPF in this claims database increased with age, with a notable increase in those over 65 years. IPF is associated with a large economic and health care burden. Additional research is needed to determine how such burden might be reduced.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.